Quantcast

Latest Neural Stem Cell Stories

2014-08-08 11:20:47

Cell Transplantation Center of Excellence for Aging and Brain Repair Induced immunorejection may eliminate tumors post-cell transplantation Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation. In an...

2014-08-08 08:25:57

GERMANTOWN, Md., Aug. 8, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and six months ended June 30, 2014 and provided a business and clinical update. "We are pleased to report that 2014 has already seen the company achieve several major milestones. In late July, we completed the last of the surgeries in the NSI-566/ALS Phase II trial. Each of the patients in the final cohort have received a total of 16 million NSI-566 neural...

2014-07-15 23:00:28

Researchers at UC Davis School of Medicine have for the first time shown that a polysialylated glycoprotein that regulates neurodevelopment exists on the surface of cells in the adult inner ear. Sacramento, Calif. (PRWEB) July 15, 2014 Researchers at UC Davis School of Medicine have for the first time shown that a polysialylated glycoprotein that regulates neurodevelopment exists on the surface of cells in the adult inner ear. This biomarker of early cells allows researchers to identify...

2014-06-02 23:09:54

Stem Cell Research Products Market says full-year 2013 analysis determines the size of the stem cell research products market to be $3.22 billion, and the stem cell therapies market to be $3.31 billion, for a total of $6.53 billion. Dallas, Texas (PRWEB) June 02, 2014 According to report “Stem Cell Research Products Market - Opportunities, Tools, and Technologies” as of 2014, several broad categories of stem cells exist, including:     Embryonic stem cells,...

2014-05-16 08:27:03

/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress, on Thursday, May 22, at 11:35 a.m. BST in London, UK (http://www.terrapinn.com/conference/stem-cells/index.stm). Neuralstem is currently in a Phase II clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its NSI-566 stem cells and has been approved to commence a Phase I study in spinal cord...

2014-04-16 11:43:12

UC Irvine neurobiologists have found that genetically modified neural stem cells show positive results when transplanted into the brains of mice with the symptoms and pathology of Alzheimer's disease. The pre-clinical trial is published in the journal Stem Cells Research and Therapy, and the approach has been shown to work in two different mouse models. Alzheimer's disease, one of the most common forms of dementia, is associated with accumulation of the protein amyloid-beta in the brain in...

2014-04-09 12:31:28

DUBLIN, April 9, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/kbp6dj/strategic) has announced the addition of the "Strategic Development of Neural Stem & Progenitor Cell Products - 2013 Update" [http://www.researchandmarkets.com/research/kbp6dj/strategic ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Neurogenesis is the process by which neurons are created. This process is most...

2014-02-18 23:27:09

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent and Trademark Office. San Diego, CA (PRWEB) February 18, 2014 Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the company has been issued...

2014-01-28 12:29:52

DUBLIN, January 28, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/6l52c9/strategic) has announced the addition of the "Strategic Development of Neural Stem & Progenitor Cell Products - 2014 Update" [http://www.researchandmarkets.com/research/6l52c9/strategic ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Neurogenesis is the process by which neurons are created. This process is...

2014-01-13 12:27:02

ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor deficits from ischemic stroke at BaYi Brain Hospital in Beijing, China. The patient received treatment on December 27, 2013 and has now returned home. The trial is sponsored by Neuralstem's wholly-owned subsidiary, Neuralstem China (Suzhou Sun-Now Biopharmaceutical Co. Ltd.), which was formed to develop...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'